Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Chichuebis Sameditsino … | Healthcare Services | 12.5% | 57th pct | 268 |
| Telavis Tsentraluri Saa… | Healthcare Services | 5.0% | 35th pct | 268 |
| Telavis Raionuli Saavad… | Healthcare Services | 5.0% | 35th pct | 268 |
| Peromedi | Healthcare Services | -7.7% | 15th pct | 268 |
| Bomondi | Healthcare Services | -51.2% | 4th pct | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
| Ratio — FY 2024 | Chichuebis Sameditsino … | Peromedi | Telavis Tsentraluri Saa… | Telavis Raionuli Saavad… | Bomondi |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 86.2% | 63.1% | 83.8% | 83.8% | 74.8% |
| EBITDA Margin | 12.5% | -7.7% | 5.0% | 5.0% | -51.2% |
| EBITDAR | 976 | -585 | 372 | 372 | -3,273 |
| EBITDAR Margin | 12.6% | -7.7% | 5.3% | 5.3% | -51.2% |
| EBIT Margin | 8.2% | -14.0% | -3.4% | -3.4% | -72.7% |
| Net Profit Margin | 7.8% | -14.2% | 6.1% | 6.1% | -106.4% |
| Operating Expense % of Sales | 73.7% | 70.8% | 78.8% | 78.8% | 126.0% |
| Returns | |||||
| Return on Assets (ROA) | 7.3% | -11.7% | 10.6% | 10.6% | -38.7% |
| Return on Equity (ROE) | 10.1% | -19.0% | 18.8% | 18.8% | N/A |
| ROIC [EBIT / Invested Capital] | |||||
| 10.7% |
| -17.2% |
| -7.6% |
| -7.6% |
| -46.6% |
| Leverage & debt balances | |||||
| Debt-to-Assets | 4.5% | 5.6% | 31.0% | 31.0% | 94.1% |
| Debt-to-Equity | 0.06x | 0.09x | 0.55x | 0.55x | -2.55x |
| Debt-to-EBITDA | 0.38x | N/A | 3.58x | 3.58x | N/A |
| Equity-to-Assets | 72.5% | 61.9% | 56.6% | 56.6% | -36.9% |
| Net Debt | -3 | 474 | 884 | 884 | 16,443 |
| Cash & Equivalents | 376 | 47 | 357 | 357 | 73 |
| Total Debt | 373 | 521 | 1,240 | 1,240 | 16,515 |
| Liquidity & working capital | |||||
| Current Ratio | 0.92x | 0.13x | 3.08x | 3.08x | 0.78x |
| Quick Ratio | 0.92x | 0.13x | 3.08x | 3.08x | 0.77x |
| Cash Ratio | 0.18x | 0.02x | 0.72x | 0.72x | 0.01x |
| Total Current Assets | 1,968 | 364 | 1,530 | 1,530 | 5,850 |
| Total Current Liabilities | 2,133 | 2,762 | 497 | 497 | 7,514 |
| Inventory | N/A | N/A | N/A | N/A | 64 |
| Trade Receivables | 1,212 | 1,504 | 1,019 | 1,019 | 2,087 |
| Trade Payables | 720 | 1,190 | N/A | N/A | 1,399 |
| Net Working Capital | -165 | -2,398 | 1,033 | 1,033 | -1,664 |
| Net Working Capital % of Revenue | -2.1% | -31.5% | 14.8% | 14.8% | -26.0% |
| Trade Working Capital | 492 | 314 | 1,019 | 1,019 | 752 |
| Trade Working Capital % of Revenue | 6.3% | 4.1% | 14.6% | 14.6% | 11.8% |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | N/A |
| Turnover & efficiency | |||||
| Inventory Turnover | N/A | N/A | N/A | N/A | 25.04x |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | 14.6 |
| Receivables Turnover | 6.39x | 5.07x | 6.86x | 6.86x | 3.06x |
| Days Sales Outstanding (DSO) | 57.1 | 72.0 | 53.2 | 53.2 | 119.2 |
| Payables Turnover | 1.49x | 2.36x | N/A | N/A | 1.15x |
| Days Payable Outstanding (DPO) | 245.2 | 154.4 | N/A | N/A | 316.9 |
| Cash Conversion Cycle | -188.1 days | -82.4 days | 53.2 days | 53.2 days | -183.1 days |
| Asset Turnover | 0.94x | 0.83x | 1.75x | 1.75x | 0.36x |
| Cash flow & dividends | |||||
| Operating Cash Flow | 672 | -6 | 112 | 112 | -128 |
| Free Cash Flow (OCF − Capex proxy) | 58 | -6 | 112 | 112 | -128 |
| Cash Conversion (OCF / EBITDA) | 69.3% | N/A | 32.5% | 32.5% | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | 0 |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A |